-
公开(公告)号:CS347091A3
公开(公告)日:1992-06-17
申请号:CS347091
申请日:1991-11-15
Applicant: HOECHST AG
IPC: A61K31/41 , A61K31/415 , A61K31/42 , A61K31/425 , A61K31/495 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/88 , C07D249/04 , C07D249/08 , C07D257/04 , C07D403/10 , C07D403/14 , C07D405/10 , C07D409/10 , C07D411/10 , C07D413/10 , C07D207/325 , C07D231/12 , A61K31/40
Abstract: Azoles of the formula in which X, Y and Z represent N or CR , L denotes alkylene, A denotes an aromatic or heterocyclic radical and T denotes a bond or a bivalent radical and R , R and E are as defined in the description. A process for their preparation, compositions containing these compounds and their application as medicines are also described.
-
公开(公告)号:CS225991A3
公开(公告)日:1992-06-17
申请号:CS225991
申请日:1991-07-19
Applicant: HOECHST AG
IPC: A61K31/415 , A61K31/4164 , A61K31/42 , A61K31/425 , A61K31/44 , A61K31/495 , A61K31/505 , A61P1/16 , A61P9/00 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/12 , A61P43/00 , C07D233/56 , C07D233/90 , C07D403/10 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D473/00 , C07D487/04 , C07D498/04 , C07D513/04 , C07D207/325 , C07D231/12 , C07D233/54 , C07D249/04 , C07D249/08 , C07D257/04 , A61K31/40 , A61K31/41
Abstract: Substd. azole derivs. of formula (I) and their physiologically acceptable salts are new. In (I) X, Y and Z are each N or CR2 R1 is 2-10C alkyl, 3-10C alkenyl, 3-10C alkynyl, -(CH2)mB(CH2nR4 (these 4 gps. opt. monosubstd. with CO2R3 and opt. have 1-all H atoms replaced by F), OR3, 3-8C cycloalkyl, 5-10C cycloalkylalkynyl, or benzyl (opt. mono or disubstd. on the Ph ring with halogen, 1-4C alkoxy and/or NO2), R2 = H, halogen, CvF2v+1, SF5, pentafluoro phenyl CN, phenyl, -(CH2)nF, -(CH2)nONO2, -CH2N3, -(CH2)nNO2, phthalimido (CH2)n-, R3 = H, 1-8C alkyl (in which 1 to all H are replaced by F), 3-8C cycloalkyl, Ph or benzyl, R4 = H, 1-6C alkyl, 3-8C cycloalkyl, 2-4C alkenyl, or 2-4C alkynyl, A = a mono or bicyclic unsatd. or partially hydrogenated heterocycle gp. with 5-10 ring atom of which up to 9 are C, and opt. substd. with up to 3 opt. different R14 gps. or -(CH2)n-1-(CHR6CH2)0-1, R14 where R14 = halogen, oxo, nitroso, NO2, amino, CN, OH, 1-6C alkyl, 1-4C alkanoyl, 1-4C alkanoyloxy. B = O, NR7 or S, W = O or S, L = 1-3C alkanediyl, R26 and R27 are each H, halogen, NO2, 1-4C alkyl or 1-2C alkoxy, n = 1-5, o = 1-10, q = 0-1.
-
公开(公告)号:CS397990A3
公开(公告)日:1992-03-18
申请号:CS397990
申请日:1990-08-13
Applicant: HOECHST AG
Inventor: HENKE STEPHAN DR , BREIPOHL GERHARD DR , KNOLLE JOCHEN DR , SCHOLKENS BERNWARD PROF DR , GERHARDS HERMANN DE
Abstract: Peptides of the formula I A-B-C-E-F-K-(D)-Phe-G-M-F'-I (1> in which A is hydrogen, alkyl, alkanoyl, alkoxycarbonyl, alkylsulphonyl, cycloalkyl, aryl, aryloyl, arylsulphonyl, heteroaryl or an amino acid, each of which can optionally be substituted, B is a basic amino acid, C is a di- or tripeptide, E is the residue of an aromatic amino acid, F is, independently of one another, an amino acid which is optionally substituted in the side chain or is a direct bond, G is an amino acid, F' is defined as F or can be -NH-(CH2)2-8 or optionally a direct bond, I is -OH, -NH2 or -NHC2H5, and K is a radical -NH-(CH2)1-4-CO- or is a direct bond, act as bradykinin antagonists. Their therapeutic uses comprise all pathological states promoted, induced or assisted by bradykinin and bradykinin-related peptides. The peptides of the formula I are prepared by known methods of peptide synthesis.
-
公开(公告)号:CZ9800914A3
公开(公告)日:1998-10-14
申请号:CZ91498
申请日:1998-03-25
Applicant: HOECHST AG
Inventor: HEITSCH HOLGER DR , WAGNER ADALBERT DR , WIRTH KLAUS DR , SCHOLKENS BERNWARD PROF DR
IPC: C07D215/24 , A61K31/395 , A61K31/47 , A61K31/495 , A61P1/16 , A61P43/00 , C07D215/26 , C07D241/36 , C07D401/12 , C07D405/12
CPC classification number: C07D401/12 , C07D215/26 , C07D405/12
-
公开(公告)号:CZ91498A3
公开(公告)日:1998-10-14
申请号:CZ91498
申请日:1998-03-25
Applicant: HOECHST AG
Inventor: HEITSCH HOLGER DR , WAGNER ADALBERT DR , WIRTH KLAUS DR , SCHOLKENS BERNWARD PROF DR
IPC: C07D215/24 , A61K31/395 , A61K31/47 , A61K31/495 , A61P1/16 , A61P43/00 , C07D215/26 , C07D241/36 , C07D401/12 , C07D405/12
Abstract: 8-Benzyloxy-(iso)quinoline derivatives (including poly-aza analogues) of formula (I) and their salts are new: D = aza-heterocyclic residue of formula (i) or (ii); X1 = N or CR6; X2 = N or CR7; X3 = N or CR8; B = benzyl variably substituted on the ring by R3-R5; R1, R2 = H, halo or 1-3C alkyl; R3, R4 = H, halo, CN, 1-3C alkyl (optionally substituted by halo), 1-3C alkoxy (optionally substituted by halo), 1-3C alkylthio (optionally substituted by halo), OH, tetrazolyl, CONHR9 or CO2R9; R5 = NO2, NH2, -NR9AYER10 or SO2NR9R10; R6, R8, R'" = H, halo, 1-4C alkyl, 1-4C alkoxy, NH2, NH-(1-4C alkyl), OH, Ar, Ar-(1-4C)-alkanediyl or CO2R9; R7, R', R" = H or 1-4C alkyl; R9 = H, 1-4C alkyl, 2-5C alkenyl or Ar-(1-3C)-alkanediyl; A = divalent residue of an aminocarboxylic acid such as methionine, alanine, phenylalanine, tyrosine, O-methyltyrosine, beta -(2-thienyl)-alanine, glycine, cyclohexylalanine, leucine, isoleucine, valine, norleucine, phenylglycine, serine, cysteine, aminopropionic acid or aminobutyric acid; Y = C=O, C=S or SO2; E = 2-5C alkene-diyl, 1-7C alkanediyl, 3-10C cycloalkanediyl or -(CH2)m-To-(CH2)n (all optionally substituted by one or more groups such as OR12, NO2, CN, CO2R9, NR13R14, SO3R12, SO2NR13R14 or CONR13R14); T = O, S or NR15; m, n = 0-6; o = 0 or 1; p = 1-3; R10 = H or 1-5C alkyl, Ar', Ar'-(1-3C)-alkanediyl or 5-10C heteroaryl (all optionally substituted by one or more groups such as halo, NO2, 1-5C alkylthio, NR13R14, NR13COR16, CO2R9, SO3R12, SO2NR13R14, OR12 or 1-6C alkyl, or Ar', 2-5C alkenyl or OA5 (themselves optionally partially or completely substituted by halo)); R11 = 1-5C alkyl or 1-5C alkoxy (both optionally partially or completely substituted by F or Cl); R12, R13 = H, 1-5C alkyl, 2-5C alkenyl, Ar, Ar-(1-5C)-alkanediyl, 3-10C cycloalkyl, (3-10C)-cycloalkyl-(1-2C)-alkanediyl, CO2-(1-5C alkyl) or CONH-(1-5C alkyl); R14 = H, CO2-(1-3C alkyl) or CO2-(1-3C)-alkanediyl-Ar'; R15 = H, CO2-(1-3C alkyl) or 1-3C alkyl; R16 = 1-3C alkyl, Ar or 5-10C heteroaryl (all optionally substituted by one or more groups such as halo, CN, NO2, NR13R14 or CO2R9); Ar, Ar' = aryl with 6-12C or 6-10C respectively; provided that if D = (ii), then R3 and R4 are not both halo, 1-3C and/or 1-3C alkoxy or H in combination with halo, 1-3C alkyl or 1-3C alkoxy, excluded from this proviso being compounds in which: (a) R5 = -N(R9)-A-Y-E-R10 and R10 = (R11)p-substituted phenyl, provided that if R10 = (R11)p-substituted phenyl then R3 and R4 are not same or different H and halo; and (b) R5 = -SO2NR9R10, provided that R3 and R4 are not both halo.
-
公开(公告)号:CZ283236B6
公开(公告)日:1998-02-18
申请号:CS347191
申请日:1991-11-15
Applicant: HOECHST AG
Inventor: HEITSCH HOLGER DR , HENNING RAINER DR , LINZ WOLFGANG DR , SCHOLKENS BERNWARD PROF DR , URBACH HANSJORG DR
IPC: A61K31/41 , A61K31/415 , A61K31/495 , A61K31/675 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/04 , C07D249/08 , C07D257/04 , C07D403/10
Abstract: The invention relates to a method for the treatment of cardiac and of vascular hypertrophy and/or hyperplasia by administration of angiotensin II receptor blockers, preferably of the imidazole, pyrrole, pyrazole, triazole or tetrazole type.
-
公开(公告)号:ID16952A
公开(公告)日:1997-11-27
申请号:ID971699
申请日:1997-05-21
Applicant: HOECHST AG
Inventor: WAGNER ADALBERT DR , HEITSCH HOLGER DR , NOLKEN GERHARD DR , WIRTH KLAUS DR , SCHOLKENS BERNWARD PROF DR
IPC: C07D277/60 , A61K31/38 , A61K31/395 , A61K31/41 , A61K31/425 , A61K31/428 , A61K31/53 , A61P43/00 , C07D253/10 , C07D277/62 , C07D277/64 , C07D277/66 , C07D277/68 , C07D277/70 , C07D277/74 , C07D277/82 , C07D417/12
Abstract: Sulphur-containing bradykinin antagonist compounds of formula (I) and their salts are claimed: one of X1-X3 = COR , and the other X1-X4 = N, CR ; R ,R = H, halo, 1-6C alkyl, OR , SR , NHR , 6-12C aryl, (6-12C aryl)(1-3C alkyl), C(O)OR , C(O)H, 2-5C alkenyl, NO2, SO3R , CN, C(O)NHR , where alkyl, aryl, alkenyl may be substituted by C(O)(O)o(1-5C alkyl), OR , SR , NO2, CN, NHR , halo; R = (II); R ,R = e.g. H; R -R = H, 1-5C alkyl, 3-5C alkenyl, etc.; A = amino acid e.g. methionine, alanine, phenylalanine, etc.; R = H, C(O)(O)o(1-5C alkyl), C(O)(O)o(11-3C alkyl)(6-10C aryl); R = e.g. C(O)DE; D = 2-5C alkendiyl, 1-8C alkandiyl, (CH2)nYo(CH2)m, etc., where any of the groups are optionally substituted by e.g. OR ; E = H, 6-10C aryl, 1-9C heteroaryl, etc.;Y = O, S, NR ; n,m = 0-6; o = 0 or 1.
-
公开(公告)号:ES2099102T3
公开(公告)日:1997-05-16
申请号:ES91106663
申请日:1991-04-25
Applicant: HOECHST AG
Inventor: BREIPOHL GERHARD DR , HENKE STEPHAN DR , KNOLLE JOCHEN DR , SCHOLKENS BERNWARD PROF DR , HOCK FRANZ DR
Abstract: Peptides of the formula I A-B-C-E-F-K-(D)-Tic-G-M-F'-I (I> in which A is hydrogen, alkyl, alkanoyl, alkoxycarbonyl, alkylsulphonyl, cycloalkyl, aryl, arylsulphonyl, heteroaryl or an amino acid, each of which can optionally be substituted, B is a basic amino acid, C is a di- or tripeptide, E is the residue of an aliphatic or alicyclic-aliphatic amino acid, F is, independently of one another, an amino acid which is optionally substituted in the side chain or is a direct bond, G is an amino acid, F' is defined as F, can be -NH-(CH2)2-8 or a direct bond, I is -OH, -NH2 or -NHC2H5, and K is a radical -NH-(CH2)1-4-CO-, or is a direct bond, have a bradykinin-antagonistic action. Their therapeutic uses comprise all pathological states which are mediated, induced or assisted by bradykinin and bradykinin-related peptides. The peptides of the formula I are prepared by known methods of peptide synthesis.
-
公开(公告)号:CZ280682B6
公开(公告)日:1996-04-17
申请号:CS116591
申请日:1991-04-24
Applicant: HOECHST AG
Inventor: BREIPOHL GERHARD DR , HENKE STEPHAN DR , KNOLLE JOCHEN DR , SCHOLKENS BERNWARD PROF DR , HOCK FRANZ DR
Abstract: Peptides of the formula I A-B-C-E-F-K-(D)-Tic-G-M-F'-I (I> in which A is hydrogen, alkyl, alkanoyl, alkoxycarbonyl, alkylsulphonyl, cycloalkyl, aryl, arylsulphonyl, heteroaryl or an amino acid, each of which can optionally be substituted, B is a basic amino acid, C is a di- or tripeptide, E is the residue of an aliphatic or alicyclic-aliphatic amino acid, F is, independently of one another, an amino acid which is optionally substituted in the side chain or is a direct bond, G is an amino acid, F' is defined as F, can be -NH-(CH2)2-8 or a direct bond, I is -OH, -NH2 or -NHC2H5, and K is a radical -NH-(CH2)1-4-CO-, or is a direct bond, have a bradykinin-antagonistic action. Their therapeutic uses comprise all pathological states which are mediated, induced or assisted by bradykinin and bradykinin-related peptides. The peptides of the formula I are prepared by known methods of peptide synthesis.
-
30.
公开(公告)号:CZ280584B6
公开(公告)日:1996-02-14
申请号:CS225991
申请日:1991-07-19
Applicant: HOECHST AG
IPC: A61K31/415 , A61K31/4164 , A61K31/42 , A61K31/425 , A61K31/44 , A61K31/495 , A61K31/505 , A61P1/16 , A61P9/00 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/12 , A61P43/00 , C07D233/56 , C07D233/90 , C07D403/10 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D473/00 , C07D487/04 , C07D498/04 , C07D513/04
Abstract: Substd. azole derivs. of formula (I) and their physiologically acceptable salts are new. In (I) X, Y and Z are each N or CR2 R1 is 2-10C alkyl, 3-10C alkenyl, 3-10C alkynyl, -(CH2)mB(CH2nR4 (these 4 gps. opt. monosubstd. with CO2R3 and opt. have 1-all H atoms replaced by F), OR3, 3-8C cycloalkyl, 5-10C cycloalkylalkynyl, or benzyl (opt. mono or disubstd. on the Ph ring with halogen, 1-4C alkoxy and/or NO2), R2 = H, halogen, CvF2v+1, SF5, pentafluoro phenyl CN, phenyl, -(CH2)nF, -(CH2)nONO2, -CH2N3, -(CH2)nNO2, phthalimido (CH2)n-, R3 = H, 1-8C alkyl (in which 1 to all H are replaced by F), 3-8C cycloalkyl, Ph or benzyl, R4 = H, 1-6C alkyl, 3-8C cycloalkyl, 2-4C alkenyl, or 2-4C alkynyl, A = a mono or bicyclic unsatd. or partially hydrogenated heterocycle gp. with 5-10 ring atom of which up to 9 are C, and opt. substd. with up to 3 opt. different R14 gps. or -(CH2)n-1-(CHR6CH2)0-1, R14 where R14 = halogen, oxo, nitroso, NO2, amino, CN, OH, 1-6C alkyl, 1-4C alkanoyl, 1-4C alkanoyloxy. B = O, NR7 or S, W = O or S, L = 1-3C alkanediyl, R26 and R27 are each H, halogen, NO2, 1-4C alkyl or 1-2C alkoxy, n = 1-5, o = 1-10, q = 0-1.
-
-
-
-
-
-
-
-
-